Kailera Q2 net loss widens to $111.3M; cash $1.17B funds into mid-2028

Kailera Therapeutics, Inc.

Net loss $111.3M in Q2 2026 vs $28.9M in Q2 2025; R&D expense $101.1M (up from $19.5M).
Cash, equivalents and marketable securities $1,171.8M, expected to fund operations into mid-2028.
Ribupatide oral IND active; global Phase 3 obesity trial initiations planned for H1 2027.
Phase 2b high-dose ribupatide injection trial fully enrolled (264 pts); data expected mid-2027.
Appointed Nur Nicholson as CTO and Kathleen Tregoning as Chief Corporate Affairs Officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.